Estrella Immunopharma Inc (ESLA) Stock Price, Quote & News

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 318 9098

Website: www.estrellabio.com

Address:

5858 Horton Street, Suite 370, EmeryVille, United States

GoldenPanth Apr. 9 at 4:58 PM

$PDSB $ESLA $CETX $ANL ^12^

0 · Reply

GoldenPanth Apr. 9 at 2:41 PM

$GRNQ $ESLA $GAUZ $BBGI <>3

0 · Reply

SuggaSean Apr. 8 at 9:11 PM

$ESLA reversal incming

0 · Reply

RoseyTheStone Apr. 8 at 3:54 PM

$ESLA Registered warrants at $1.39 making it hard for this to move up further. Heavy supply of located available — when’s the PR? Asking for a friend…

0 · Reply

Arcides Apr. 7 at 9:45 PM

$BMEA $ESLA $PRLD on fire

0 · Reply

Soyaz Apr. 7 at 3:06 PM

$ESLA

0 · Reply

SuggaSean Apr. 7 at 1:09 AM

$ESLA

0 · Reply

RoyalsPalaceTrades Apr. 7 at 12:59 AM

Insane alert man, Thanks for calling it early. That @ElevenXProfits is a good bull to Follow bellow, He's been keeping me green in this dead market 💯🔥 Eyes on $RCMT $AGL $ESLA $AIB tomorrow too

0 · Reply

neangewo Apr. 6 at 5:21 PM

$ESLA Up on big volume and no news! Took a starter for a swing!

0 · Reply

ZacksSCR Mar. 26 at 8:39 PM

CAR-T therapy has reshaped oncology, but toxicity and durability remain challenges. $ESLA's ARTEMIS® platform is built to address both. Zacks SCR initiates coverage with early STARLIGHT-1 data showing a 100% CR rate at dose level 2. #CARTCell #Biotech #Oncology #SmallCap https://youtu.be/JoD4rNMoY-s

1 · Reply

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

Feb 9, 2026, 7:00 AM EST - 2 months ago

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Feb 3, 2026, 8:00 AM EST - 2 months ago

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Jan 6, 2026, 2:02 PM EST - 3 months ago

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Jan 5, 2026, 8:30 AM EST - 3 months ago

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Dec 4, 2025, 8:00 AM EST - 4 months ago

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Nov 3, 2025, 8:00 AM EST - 5 months ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Oct 6, 2025, 8:00 AM EDT - 6 months ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Jun 5, 2025, 8:00 AM EDT - 11 months ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 3, 2025, 8:00 AM EDT - 11 months ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

May 29, 2025, 8:01 AM EDT - 11 months ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Mar 5, 2025, 8:00 AM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Feb 21, 2025, 8:30 AM EST - 1 year ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 19, 2025, 4:46 PM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

GoldenPanth Apr. 9 at 4:58 PM

$PDSB $ESLA $CETX $ANL ^12^

0 · Reply

GoldenPanth Apr. 9 at 2:41 PM

$GRNQ $ESLA $GAUZ $BBGI <>3

0 · Reply

SuggaSean Apr. 8 at 9:11 PM

$ESLA reversal incming

0 · Reply

RoseyTheStone Apr. 8 at 3:54 PM

$ESLA Registered warrants at $1.39 making it hard for this to move up further. Heavy supply of located available — when’s the PR? Asking for a friend…

0 · Reply

Arcides Apr. 7 at 9:45 PM

$BMEA $ESLA $PRLD on fire

0 · Reply

Soyaz Apr. 7 at 3:06 PM

$ESLA

0 · Reply

SuggaSean Apr. 7 at 1:09 AM

$ESLA

0 · Reply

RoyalsPalaceTrades Apr. 7 at 12:59 AM

Insane alert man, Thanks for calling it early. That @ElevenXProfits is a good bull to Follow bellow, He's been keeping me green in this dead market 💯🔥 Eyes on $RCMT $AGL $ESLA $AIB tomorrow too

0 · Reply

neangewo Apr. 6 at 5:21 PM

$ESLA Up on big volume and no news! Took a starter for a swing!

0 · Reply

ZacksSCR Mar. 26 at 8:39 PM

1 · Reply

ZacksSCR Mar. 18 at 1:23 PM

$ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T https://buff.ly/hJfckaA

0 · Reply

BonjerminFranklin Mar. 6 at 2:07 PM

$ESLA wtf happen😂.. another rinse and repeat moment!

0 · Reply

OfficialStocktwitsUser Mar. 3 at 1:02 AM

$ESLA RSI: 21.78, MACD: -0.0183 Vol: 0.10, MA20: 1.24, MA50: 1.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 22 at 10:22 PM

$ESLA Current Stock Price: $1.18

0 · Reply

Pb1782 Feb. 13 at 3:43 PM

$ESLA

0 · Reply

GammaForager Feb. 10 at 2:58 PM

$ESLA is a esla or energy company; name suggests clean energy, a competitive sector.

0 · Reply

BillionerOfKing Feb. 10 at 4:21 AM

$ESLA Current Stock Price: $1.42

0 · Reply

ZacksSCR Feb. 9 at 7:04 PM

$ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL https://buff.ly/zdOT8JR

0 · Reply

neangewo Feb. 9 at 12:40 PM

$ESLA PR is out and the headline could not be any better! Will the price run up though? We shall see.

0 · Reply

neangewo Feb. 9 at 1:54 AM

$ESLA PR AM tomorrow?

0 · Reply

Market Cap	81.92M
Revenue (ttm)	0.00
Net Income (ttm)	-13.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	130,800
Avg Vol	238,812
Day's Range	N/A - N/A
Shares Out	42.67M
Stochastic %K	77%
Beta	0.58
Analysts	Strong Sell
Price Target	$10.00